Archive for Февраль 6th, 2007
Study: Acomplia Produces Weight Loss and Metabolic Improvement
Quebec City, Canada, March 9, 2004 - Results of a Phase III clinical trial (RIO-Lipids or Rimonabant In Obesity) comparing rimonabant, the first drug in a new Acomplia (rimonabant) class called Selective CB1 Blockers (or SCB1Bs), to placebo found that overweight or obese patients with untreated [...]
Interim Trial Results Support Earlier Study on Acomplia Benefit
First year results of the two year trial Rimonabant In Obesity - Europe (RIO–Europe), a Phase III clinical study comparing placebo to rimonabant, the Acomplia (rimonabant) first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) blockers, showed that overweight or obese people [...]
